Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024559 | 1.00 | HTR1A (0.45) | HTR1AHTR1DHTR1BKMT2AMEN1 | |
| Cyclopropane SCHEMBL5024489 | 0.91 | MEN1 (0.44) | KMT2AMEN1ALDH1A1PIN1 | |
| SCHEMBL5028642 | 0.91 | HTR1A (0.46) | HTR1AHTR1DHTR1BKMT2AMEN1 | |
| SCHEMBL5028647 | 0.91 | HTR1A (0.46) | HTR1AHTR1DHTR1BKMT2AMEN1 | |
| SCHEMBL5024376 | 0.90 | HTR1A (0.46) | HTR1AHTR1DHTR1BKMT2AMEN1 | |
| SCHEMBL5024379 | 0.90 | HTR1A (0.46) | HTR1AHTR1DHTR1BKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5025325 | 0.89 | HTR1A (0.46) | HTR1AHTR1DHTR1BKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5025321 | 0.89 | HTR1A (0.46) | HTR1AHTR1DHTR1BKMT2AMEN1 | |
| SCHEMBL5024483 | 0.89 | MCHR1 (0.43) | — | |
| SCHEMBL5024485 | 0.89 | MCHR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474145-B1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | claimed |
| US-6696467-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-24 | — | — | US | claimed |
| US-20030153553-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | claimed |
| EP-1474145-B1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-6696467-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030153553-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153553-A1 | Quinoline derivatives | NPY1R, NPY4R, GLP1R | HTR1A 157/4885HTR1D 149/4885HTR1B 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.